

British Association for Sexual Health and HIV national guideline for the management of Genital Molluscum in adults (2021)

International Journal of STD & AIDS
2022, Vol. 33(5) 422–432
© The Author(s) 2022
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/09564624211070705
journals.sagepub.com/home/std


Imali Fernando¹, Sarah K Edwards² and Deepa Grover³ 

Abstract

This guideline offers recommendations on diagnosis, treatment regimens and health promotion principles needed for the effective management of genital molluscum, including management of the initial presentation and recurrences. The Primary focus of the guideline is on infection which affects the genital area and has a sexual mode of transmission. This is an update to the guideline previously published in this journal in 2014.

Keywords

Molluscum < viral disease

Date received: 29 November 2021; revised: 8 December 2021; accepted: 9 December 2021

New in the 2021 guidelines

Some key treatment options have been revised following the availability of previously unpublished trial data in most recent Cochrane review of cutaneous molluscum therapies: imiquimod is no longer recommended as a treatment for genital molluscum.

We have included a summary table of treatment recommendations for ease of use.

GRADE levels have been provided for recommended therapies (see GRADE methodology in guideline framework document) <https://www.bashhguidelines.org/media/1229/2015-guidelines-framework-amended-dec-2019.pdf>

Introduction and methodology

Objectives

This guideline offers recommendations on diagnosis, treatment regimens and health promotion principles needed for the effective management of genital molluscum, including management of the initial presentation and recurrences. *The primary focus is on infection which affects the genital area and has a sexual mode of transmission.*

The guideline is aimed primarily at patients aged 16 years or older presenting to healthcare professionals working in departments offering level 3 care in STI management within the United Kingdom. However, the principles of the recommendations should be adopted across all levels; level 1 and 2 providers may need to develop local care pathways where appropriate.

Search strategy

PICO questions were set as:

POPULATIONS: individuals with genital molluscum contagiosum

INTERVENTION: management (including no treatment) for molluscum contagiosum

COMPARISON: no specific comparators were applied to ensure all relevant articles were picked up in the search

OUTCOME: clearance of molluscum, adverse effects

The following reference sources were used to provide a comprehensive basis for the guideline:

- Medline and Embase search (from 1980 till end of Dec 2018): the search strategy comprised the following terms in the title or abstract: Molluscum +/- contagiosum +/- genital. Only articles published in English were included in the search.
- Cochrane Collaboration Databases (www.cochrane.org) were reviewed.

¹ Chalmers Sexual Health Center, Edinburgh, UK

² GU Medicine, Cambridgeshire Community Services NHS Trust, Bury St Edmunds, UK

³ GUM/HIV Medicine, Central and North West London NHS Foundation Trust, London, UK

Corresponding author:

Deepa Grover, GUM/HIV Medicine, Central and North West London NHS Foundation Trust, London N19 5SE, UK.

Email: deepa.grover@nhs.net

➤ The British Association of Dermatology (BAD) patient information guidance, the American Academy of Dermatology (AAD) Association clinical guidance, the American Centres for Disease Prevention and Control (CDC) clinical guidance and the International Union against Sexually Transmitted Infection (IUSTI) European guideline on the management of molluscum contagiosum infection were also reviewed.

Methods

Article titles and abstracts were reviewed and if relevant, the full text article obtained. Priority was given to randomised controlled trial and systematic review evidence where available, and recommendations made and graded on the basis of best available evidence.

Piloting and feedback

The document was reviewed by the Clinical Effectiveness Group of the British Association for Sexual Health and HIV (BASHH), and their comments incorporated. The draft guideline was placed on the BASHH website for two months and any comments received during the consultation period were reviewed by the authors and acted on appropriately. The document was also piloted by target users and the public panel of BASHH, and their feedback considered by the authors.

Guideline

Aetiology

Molluscum infection is a benign epidermal eruption of the skin, caused by molluscum contagiosum, a large DNA virus. Molluscum contagiosum belongs to the *Poxviridae* family and *Molluscipox* genus.¹

Up to four subtypes of molluscum contagiosum have been identified by genotypic analysis^{2–5}; the commonest is MCV-1, followed by the MCV-2 subtype.^{6–8} However, while there appears to be no clinical difference between subtypes,^{8–9} MCV-2's relative frequency appears to increase with age and in the setting of genital infection,⁷ though MCV-1 still remains the commonest subtype. MCV-2 also appears relatively commoner in the setting of immunocompromise and HIV.^{10–12} An individual infection usually includes only one subtype of molluscum.⁷

Molluscum infection may be spread by physical contact between individuals, fomites or autoinoculation. Molluscum incidence appears to be increasing worldwide.

Molluscum infection commonly occurs in one of 3 settings:

➤ Infection acquired through routine physical contact or occasionally fomites is the commonest presentation, and

children account for the majority of infections^{13–14}. In the period 1994–2003, over 90% of molluscum infections presenting to general practitioners in the UK were in children aged under the age of 15 years.¹⁵ In this setting, the molluscum lesions usually affect face and neck, trunk or limbs.^{14,16,17}

➤ Molluscum as a sexually transmitted infection (STI), usually affecting young adults, is a very small proportion of reported infections,¹³ but may be increasing in frequency.^{18–20} Sexually transmitted molluscum lesions usually affect the genitals, pubic region, lower abdomen, upper thighs and/or buttocks.

➤ Severe molluscum infection can manifest in the context of immunocompromise, notably late stage HIV infection.

Clinical features

Molluscum lesions are usually characteristic, presenting as smooth-surfaced, firm, dome-shaped papules with central umbilication. Their colour can vary from pearly-white or pink to yellow. Lesions are usually 2–5 mm diameter, though occasionally much larger (giant mollusca), especially in the setting of immunocompromise.^{14,21,22} Other uncommon manifestations include cystic, cellulitis or abscess-like lesions,^{14,23–27} cutaneous pseudo-lymphomas,^{28–31} folliculitis^{32–33} or warty appearances.³⁴ Destruction of an individual lesion will reveal a cheesy material, containing infectious viral particles.

Commonly, patients have 1–30 individual lesions at a time,³⁵ occurring as clusters, and these can become Koebnerised. Especially lesions in later stages, at the point of regression, can be surrounded by an inflammatory dermatitis, which is due to a local inflammatory response to the infection.^{36–37} Molluscum infection can affect almost any part of the body, rarely even the oral cavity^{38–40} or sole of the foot.^{41–43} Molluscum infection of the eyes may cause keratitis.⁴⁴ Autoinoculation of other areas is possible following infection of skin at one region. Individuals with atopic dermatitis may be at higher risk of acquiring infection, due to loss of skin integrity and the immune dysregulation of atopic skin. Molluscum lesions are frequently asymptomatic, though occasionally associated with itch, discomfort or secondary bacterial infection. Molluscum lesions will usually regress spontaneously within 6–18 months on average in immunocompetent individuals, leaving no sequelae. Immunocompetent patients can therefore generally be reassured and asked to adopt a policy of 'watchful waiting'.

Molluscum infection in immunocompromised states can be significantly more aggressive and widespread, presenting with 100 or more lesions in one individual,^{45–48} and progressing as confluent, coalescing plaques.⁴⁹ As described, these individual lesions can be atypical in appearance, are frequently significantly larger than average^{50–52} and fail to spontaneously resolve with time. Extensive molluscum

infection has been described in many different settings of immunocompromise, including malignancy,⁴⁷ hereditary/congenital immunosuppressive conditions^{53–56} and with immunosuppressant treatments.^{36,52,57–59}

Severe molluscum infections were also common in people living with HIV in the pre-HAART era,^{60–61} estimated to affect 5–18% of positive individuals.^{62–65} Extensive disease usually occurs in the setting of late HIV, with CD4 counts significantly under 200 and concurrent illnesses related to advanced HIV infection.^{46,63,66–74} Extensive molluscum can be the first indication of HIV infection.⁴⁶

Lesions occur commonly on the face and neck,^{50,75} but can also commonly affect the genital regions, indicating both non-sexual and sexual transmission routes in this scenario.⁴⁶ Particularly in immunocompromise, molluscum lesions can affect the eyelids^{76–78} and cause chronic conjunctivitis due to a foreign body type reaction.^{14,77,79–81} Molluscum infection can be particularly difficult to treat in late-stage HIV using conventional means,^{64,82} though it usually responds to HIV antiretroviral treatment (ARV) initiation.⁸³ However, an immune reconstitution inflammatory syndrome (IRIS) reaction to molluscum may occur with the starting of ARVs,^{84–86} and molluscum may occasionally first present in the setting of IRIS.^{87–89}

Diagnosis

Diagnosis is predominantly clinical, on the basis of characteristic lesions.

Occasionally, clinical diagnosis can be challenging, and dermatoscopy may be of some additional benefit,^{90–91} as appearances are usually distinctive.⁹² However, dermatoscopy is not routinely available in a sexual health setting. Rarely, biopsy maybe useful for atypical infections, as the histopathology will usually identify characteristic molluscum bodies.^{36,93}

While molecular methods such as PCR now exist for molluscum,⁹⁴ these are not routinely used in clinical practice. Electron microscopic appearance of molluscum is again characteristic but not routinely utilised in everyday practice.

Differential diagnoses. Molluscum may be mistaken for a number of other dermatologic conditions, especially for solitary lesions including basal cell carcinoma (BCC), cysts and abscesses, keratoacanthoma and cutaneous horn. Genital molluscum may also be confused with ectopic sebaceous glands^{95,96} and vulvar lymphangioma circumscriptum.^{97,98} Patients may confuse genital lesions with genital warts.

The most significant differential diagnoses of widespread molluscum, however, are the cutaneous manifestations of disseminated fungal infections, usually presenting in late immunosuppression, including penicilliosis,^{99–101} cryptococcosis,^{102–110} histoplasmosis,^{111,112} coccidioidomycosis,¹¹³ *pneumocystis carinii*¹¹³ and aspergillosis.¹¹⁴

Management

General advice. Patients should be reassured that this is a benign viral infection of the skin that will commonly spontaneously resolve within 12–18 months and treatment is usually not required. Where lesions are predominantly genital, it is likely that the infection was contracted through sexual intercourse though this is not invariable (auto-inoculation from another area is possible).

Patients must be warned of risks of autoinoculation and, for example, advised against shaving, electrolysis or waxing their genital regions to prevent further spread of lesions.¹¹⁵ Similarly, patients should be advised against squeezing molluscum spots, both due to risk of super-infection and also as the central plug is full of infectious virus which is easily spread to uninfected skin.

Towels, bed-linen, clothes, etc. should not be shared when active lesions are present to reduce risk of onward transmission. Lesions should be covered with waterproof bandages or clothes, if possible, prior to using swimming pools.¹¹⁶

With genital molluscum, condoms may reduce transmission, but this is not absolute.¹¹⁷ Patients should avoid sharing sex toys while lesions are present. Treatment and full resolution of lesions will prevent further transmission.

Further investigation. Patients who develop molluscum at their genital regions have usually acquired infection via a sexual route,¹¹⁸ and should be offered routine STI screening for other infections.

In patients with immune suppression, disseminated fungal infections should be excluded.

Treatments (please see Table 1)

Recommended. Expectant management (no treatment) is recommended for immunocompetent patients (although this recommendation is guided by a Cochrane review of molluscum treatments at non-genital sites).¹¹⁹ (GRADE 1B) Patients should be warned that new lesions may appear while old ones disappear, and it will usually take 12–18 months for infection to completely resolve, though occasionally even longer (up to a few years).

Patients seek treatment from various motives, including for cosmetic reasons, stigma, symptoms (pruritus, secondary infection), extensive lesions, lesion persistence and concerns regarding transmission and autoinoculation. Some treatments may shorten the disease course, but this requires to be balanced against possible side-effects. Molluscum infection itself, resolving naturally, usually leaves no long-term sequelae, and it is important therefore that any therapy chosen, especially for delicate genital skin, is also gentle and has minimal side-effects. It is difficult to advocate one single treatment above others and choice is influenced by a number of factors, including site and number of lesions, comparative efficacy, side-effects, cost and ease of use. The patient's views should be

Table 1. Summary of recommendations for the treatment of genital molluscum contagiosum.

	GRADE recommendation	
Treatments for MC for people without HIV		
1.1	Expectant management (i.e. no treatment) for immunocompetent individuals with molluscum contagiosum (MC)	1B
2.1	Liquid nitrogen treatment in immunocompetent individuals with MC	2C
2.1	Podophyllotoxin 0.5% treatment in immunocompetent individuals with MC	2C
2.1	Emollients and mild topical steroid for severe dermatitis associated with MC lesions	2C
3.1	Imiquimod in immunocompetent individuals with MC	Not recommended
4.1	Treatments for MC for people living with HIV	2D
	1. Liquid nitrogen	2D
	2. Podophyllotoxin 0.5%	
4.2	For extensive MC lesions in immunosuppressed patients, the introduction of antiretroviral therapy (ART) is recommended	1C

considered in the decision-making process. If patients opt for treatment, they must be informed that new lesions can appear for a while, necessitating more than one treatment course.

Where molluscum lesions are associated with dermatitis (either due to background atopy or as an immune reaction to lesions), we suggest considering emollients and possibly mild topical steroid to settle inflammation, reduce the risk of scratching and further autoinoculation.¹²⁰ (GRADE 2C) Where active treatment for genital molluscum is required, we suggest that liquid nitrogen therapy or topical podophyllotoxin may be used. (GRADE 2C)

Liquid nitrogen therapy has been successfully used to treat molluscum,^{121–124} although there are no reported trials in genital disease. Discomfort during application and local site reactions, uncommonly including hypopigmentation, are among the side-effects.

Podophyllotoxin 0.5%, commonly used to treat genital warts, may also be used in the treatment of molluscum contagiosum. We note evidence on efficacy is somewhat limited,^{121,125,126} however in one randomised controlled trial (RCT) which demonstrated success, the majority of patients had genital lesions.¹²⁵ Podophyllotoxin has the advantage of self-application and should be used twice daily for three consecutive days every week, for up to a duration of 4 weeks [net price 3 ml solution £12.38].

Alternative regimens. Cautery of genital molluscum is possible, especially if lesion numbers are not large.¹¹⁹ Side-effects of scarring is unlikely if it is performed expertly and only to the raised dome of the lesions. However, cautery is often painful, though discomfort may be lessened by the prior application of local anaesthetic cream (e.g. EMLA cream). In addition, equipment necessary for cautery is unlikely to be easily accessible within most sexual health services.

Curettage is a conventional and well-recognised treatment for molluscum affecting non-facial, non-genital skin,¹²⁷ but is frequently painful,¹²⁸ impractical if a very large number of lesions are present, may cause scarring and evidence for its efficacy is relatively sparse.^{129–130} It is thus less suitable for treating genital lesions.

Light-emitting and pulsed dye lasers have been tried with some success in both HIV-positive and -negative patients with non-genital molluscum, though there are no randomised controlled trials. Reported side-effects are few; mild discomfort and usually, temporary, pigment changes.^{131–138} However, such treatment is costly, requires special equipment and is impractical for routine use at the genital region.

Imiquimod 5% cream has demonstrated some limited efficacy in the treatment of molluscum contagiosum, in both HIV-positive^{48,139–141} and -negative patients.^{142–146} There is also some experience in the use of imiquimod to treat genital infection.^{147,148} However, the most recent Cochrane review of molluscum therapies¹¹⁹ considered previously unpublished data from three large manufacturer sponsored trials, including a total of over 800 patients, enquiring into the efficacy of imiquimod as treatment for cutaneous molluscum. The trials failed to demonstrate any superiority of imiquimod above placebo in the treatment of molluscum but did note an increased incidence of local application site reactions. Taking these data into account, we therefore no longer recommend imiquimod as a treatment option for genital molluscum infection.

There is a very extensive list of other chemical preparations that have been tried for treating molluscum on the trunk and limb areas of the body. These include varying strength topical preparations of salicylic acid,^{127,149,150} lactic acid, glycolic acid,¹²⁷ trichloroacetic acid,^{151,152} carbolic acid, benzoyl peroxide,¹⁵³ iodine,¹⁵⁰ phenol, sodium nitrite,¹⁵⁴ potassium hydroxide,^{155–159} silver nitrate,¹⁶⁰ tretinoin,^{153,159} tea tree oil¹⁶¹ and lemon myrtle oil¹⁶² However, there is little robust trial evidence generally for these treatments and none related to their use in genital infection, to recommend any above the policy of 'watchful waiting'. Additionally, many of these topical therapies are too irritant for application on delicate genital skin and thus, are not recommended for use at this site. There is more experience in the use of cantharidin for non-genital molluscum, but this treatment is not routinely available in the UK and, again, would be expected to cause significant soreness at genital skin.^{163–170}

Oral cimetidine has also been attempted as an antiviral treatment for molluscum with mixed success^{171–173} and cannot be recommended due to lack of evidence.

In summary, there are a paucity of good-quality trial data for effective and well-tolerated treatments for genital molluscum. We recommend that expectant management is suitable for most immunocompetent patients. Where there is a strong individual patient or clinician preference for active treatment, liquid nitrogen and topical podophyllotoxin can be attempted as easily accessible therapies in most UK sexual health clinic settings. Cautery may also be considered but the required equipment and experience may not be as readily available in regular sexual health service settings. We no longer recommended imiquimod use for genital molluscum.

Pregnancy and breastfeeding. Cryotherapy and cautery are safe, but podophyllotoxin should be avoided in pregnant women.

Genital molluscum infection in people living with HIV. We suggest that where active treatment is required, similar to immunocompetent individuals, liquid nitrogen and podophyllotoxin remain the first-line treatment options for genital lesions in people living with HIV (GRADE 2D).

Topical cidofovir has demonstrated some efficacy in the treatment of non-genital recalcitrant molluscum infection in the setting of HIV immunosuppression,^{174–178} but is frequently associated with significant local inflammation. It therefore cannot be recommended for use on genital skin. There are also a small number of case reports^{178–180} on the use of intravenous cidofovir for extensive, severe and treatment refractory non-genital infection in HIV. There are however no trial data available, either for genital or non-genital infection.

Both intra-lesional¹⁸¹ and systemic subcutaneous interferon^{182–183} have been attempted as immune-boosters for the treatment of molluscum in a few immunosuppressed patients. There is however again no evidence to support interferon use for routine genital infection.

As noted previously, there are also a number of case reports on the use of topical imiquimod for non-genital lesions in people living with HIV.^{48,139–141}

For patients who are immunosuppressed (with HIV infection) and have extensive genital molluscum lesions, the introduction of active antiretroviral treatment will speed resolution,^{83,184–188} and we recommend that this should be regarded the most effective management option (GRADE 1C) However, patients should be warned that there may be an occasional flare-up during immune reconstitution.^{84–86}

Reactions to treatment. Common side-effects to cryotherapy include pain, inflammation and mild oedema at treated areas. Pigment change, hair loss and superficial scarring are rare.

Podophyllotoxin is also commonly associated with local contact irritant reactions.

Follow-up. No routine follow-up is required. Patients should be advised that infection does not lie dormant once all the lesions have resolved. However, individuals do not develop immunity after one infection and may be re-infected.

Contact tracing and treatment. Routine partner notification is not required for genital molluscum infection unless there is evidence of a concomitant sexually transmitted infection.

Auditable outcomes. Offer of STI screening for patients presenting with genital molluscum—target 97%.

Cost implications. The recommended first-line treatments of cryotherapy and podophyllotoxin remain unchanged and no cost implications are expected.

This guideline was commissioned, edited and endorsed by the BASHH CEG, without external funding being sought or obtained.

Guideline updates and date of next review. The guidelines will be next fully updated and revised in 2026.

Membership of the clinical effectiveness group. Current membership of the BASHH Clinical Effectiveness Group is available at <https://www.bashh.org/guidelines>.

Declarations of conflicting interest

The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: All members of the guideline writing committee completed the BASHH conflict of interest declaration at the time the guideline's final draft was submitted to the CEG.

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sector.

ORCID iD

Deepa Grover  <https://orcid.org/0000-0002-0232-1583>

References

1. Bateman F. Molluscum contagiosum. In: Shelley WB and Crissey JT (eds). *Classics in Dermatology*. Springfield IL: Charles C Thomas; 1953, pp. 20.
2. Darai G, Reisner H, Scholz J, et al. Analysis of the genome of molluscum contagiosum virus by restriction endonuclease analysis and molecular cloning. *J Med Virol* 1986; 18(1): 29–39.
3. Porter CD and Archard LC. Characterization and physical mapping of Molluscum contagiosum virus DNA and location of a sequence capable of encoding a conserved domain of epidermal growth factor. *J Gen Virol* 1987; 68(Pt 3): 673–682.

4. Porter CD, Muhlemann MF, Cream JJ, et al. Molluscum contagiosum: characterization of viral DNA and clinical features. *Epidemiol Infect* 1987; 99(2): 563–566.
5. Porter CD and Archard LC. Characterisation by restriction mapping of three subtypes of molluscum contagiosum virus. *J Med Virol* 1992; 38: 1–6.
6. Saral Y, Kalkan A, Ozdarendeli A, et al. Detection of Molluscum contagiosum virus (MCV) subtype I as a single dominant virus subtype in Molluscum lesions from a Turkish population. *Arch Med Res* 2006; 37(3): 388–391.
7. Trčko K, Hošnjak L, Kušar B, et al. Clinical, histopathological, and virological evaluation of 203 patients with a clinical diagnosis of molluscum contagiosum. *Open Forum Infect Dis* 2018; 12(11): 5.
8. Yamashita H, Uemura T and Kawashima M. Molecular epidemiologic analysis of Japanese patients with molluscum contagiosum. *Int J Dermatol* 1996; 35: 99–105.
9. Porter CD, Blake NW, Archard LC, et al. Molluscum contagiosum virus types in genital and non-genital lesions. *Br J Dermatol* 1989; 120: 37–41.
10. Thompson CH, De Zwart-Steffe RT and Biggs IM. Molecular epidemiology of Australian isolates of molluscum contagiosum. *J Med Virol* 1990; 32(1): 1–9.
11. Thompson CH, De Zwart-Steffe RT and Donovan B. Clinical and molecular aspects of molluscum contagiosum infection in HIV-1 positive patients. *Int J STD AIDS* 1992; 3(2): 101–106.
12. Epstein WL. Molluscum Contagiosum. *Semin Dermatol* 1992; 11: 184–189.
13. Koning S, Bruijnzeels MA, van Suijlekom-Smit LW, et al. Molluscum contagiosum in Dutch general practice. *Br J Gen Pract* 1994; 44(386): 417–419.
14. Laxmisha C, Thappa DM and Jaisankar TJ. Clinical profile of molluscum contagiosum in children versus adults. *Dermatol Online J* 2003; 9(5): 1.
15. Pannell RS, Fleming DM and Cross KW. The incidence of molluscum contagiosum, scabies and lichen planus. *Epidemiol Infect* 2005; 133(6): 985–991.
16. Dohil MA, Lin P, Lee J, et al. The epidemiology of molluscum contagiosum in children. *J Am Acad Dermatol* 2006; 54(1): 47–54.
17. Kakourou T, Zachariades A, Anastasiou T, et al. Molluscum contagiosum in Greek children: a case series. *Int J Dermatol* 2005; 44(3): 221–223.
18. Becker TM, Blount JH, Douglas J, et al. Trends in molluscum contagiosum in the United States, 1966–1983. *Sex Transm Dis* 1988; 13: 88–92.
19. Kumar B, Sahoo B, Gupta S, et al. Rising incidence of genital herpes over two decades in a sexually transmitted disease clinic in north India. *J Dermatol* 2002; 29(2): 74–78.
20. Villa L, Varela JA, Otero L, et al. Molluscum contagiosum: A 20-year study in a sexually transmitted infections unit. *Sex Transm Dis* 2010; 37(7): 423–424.
21. Cribrier B, Scrivener Y and Grosshans E. Molluscum contagiosum: histologic patterns and associated lesions. A study of 578 cases. *Am J Dermatopathol* 2001; 23(2): 99–103.
22. Mulugeta A. Giant molluscum contagiosum presenting as a tumour in an HIV-infected patient: case report. *Ethiop Med J* 2000; 38(2): 125–130.
23. Park SK, Lee JY, Kim YH, et al. Molluscum contagiosum occurring in an epidermal cyst—report of 3 cases. *J Dermatol* 1992; 19(2): 119–121.
24. Egawa K, Honda Y and Ono T. Multiple giant molluscum contagiosa with cyst formation. *Am J Dermatopathol* 1995; 17(4): 414–416.
25. Freeman CL and Moriarty AT. Molluscum contagiosum presenting as cellulitis in an AIDS patient: cytologic and ultrastructural features. *Diagn Cytopathol* 1995; 12(4): 345–349.
26. Phelps A, Murphy M, Elaba Z, et al. Molluscum contagiosum virus infection in benign cutaneous epithelial cystic lesions—report of 2 cases with different pathogenesis? *Am J Dermatopathol* 2010; 32(7): 740–742.
27. Brandrup F and Asschenfeldt P. Molluscum contagiosum-induced comedo and secondary abscess formation. *Pediatr Dermatol* 1989; 6(2): 118–121.
28. Kazakov DV, Burg G, Dummer R, et al. Cutaneous lymphomas and pseudolymphomas: newly described entities. *Recent Results Cancer Res* 2002; 160: 283–293.
29. Moreno-Ramírez D, García-Escudero A, Ríos-Martín JJ, et al. Cutaneous pseudolymphoma in association with molluscum contagiosum in an elderly patient. *J Cutan Pathol* 2003; 30(7): 473.
30. Ackerman AB and Tanski EV. Pseudoleukemia cutis: report of a case in association with Molluscum Contagiosum. *Cancer* 1977; 40: 813–817.
31. de Diego J, Berridi D, Saracibar N, et al. Cutaneous pseudolymphoma in association with molluscum contagiosum. *Am J Dermatopathol* 1998; 20: 518–521.
32. Ive FA. Follicular molluscum contagiosum. *Br J Dermatol* 1985; 113(4): 493–495.
33. Jang KA, Kim SH, Choi JH, et al. Viral folliculitis on the face. *Br J Dermatol* 2000; 142(3): 555–559.
34. Itin PH and Gilli L. Molluscum contagiosum mimicking sebaceous nevus of Jadassohn, ecthyma and giant condylomata acuminata in HIV-infected patients. *Dermatology* 1994; 189(4): 396–398.
35. Gottlieb SL and Myskowski PL. Molluscum contagiosum. *Int J Dermatol* 1994; 33: 453–461.
36. Brown ST, Nalley JF and Kraus SJ. Molluscum contagiosum. *Sex Transm Dis* 1981; 8(3): 227–234.
37. Osio A, Deslandes E, Saada V, et al. Clinical characteristics of molluscum contagiosum in children in a private dermatology practice in the greater Paris area, France: a prospective study in 661 patients. *Dermatology* 2011; 222(4): 314–320.
38. Laskaris G and Sklavounou A. Molluscum contagiosum of the oral mucosa. *Oral Surg Oral Med Oral Pathol* 1984; 58(6): 688–691.
39. Whitaker SB, Wiegand SE and Budnick SD. Intraoral molluscum contagiosum. *Oral Surg Oral Med Oral Pathol* 1991; 72: 334–336.
40. Fornatora ML, Reich RF, Gray RG, et al. Intraoral molluscum contagiosum: a report of a case and a review of the literature. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2001; 92(3): 318–320.
41. Cohen PR and Tschen JA. Plantar molluscum contagiosum: a case report of Molluscum Contagiosum occurring on the

- sole of the foot and a review of the world literature. *Cutis* 2012; 90(1): 35–41.
42. Dickinson A, Tschen JA and Wolf JE, Jr. Giant molluscum contagiosum of the sole. *Cutis* 1983; 32(3): 239–243.
 43. Ha SJ, Park YM, Cho SH, et al. Solitary giant molluscum contagiosum of the sole. *Pediatr Dermatol* 1998; 15(3): 222–224.
 44. Lee OS. Keratitis occurring with molluscum contagiosum. *Arch Ophthalmol* 1944; 31: 64–67.
 45. Katzman M, Carey JT, Elmets CA, et al. Molluscum contagiosum and the acquired immunodeficiency syndrome: clinical and immunological details of two cases. *Br J Dermatol* 1987; 116: 131–138.
 46. Schwartz JJ and Myskowski PL. Molluscum contagiosum in patients with human immunodeficiency virus infection. *J Am Acad Dermatol* 1992; 27: 583–588.
 47. Nakamura-Wakatsuki T, Kato Y, Miura T, et al. Eruptive molluscum contagiosums in a patient with rheumatoid arthritis and lung cancer. *Rheumatol Int* 2011; 31(8): 1117–1118.
 48. Brown CW, O'Donoghue M, Moore J, et al. Recalcitrant molluscum contagiosum in an HIV-afflicted male treated successfully with topical Imiquimod. *Cutis* 2000; 65: 363–366.
 49. Trope BM and Lenzi ME. AIDS and HIV infections: uncommon presentations. *Clin Dermatol* 2005; 23(6): 572–580.
 50. Petersen CS and Gerstoft J. Molluscum contagiosum in HIV-infected patients. *Dermatology* 1992; 184(1): 19–21.
 51. Mansur AT, Göktay F, Gündüz S, et al. Multiple giant molluscum contagiosum in a renal transplant recipient. *Transpl Infect Dis* 2004; 6(3): 120–123.
 52. Weisenseel P, Kuznetsov AV, Flaig M, et al. Disseminated eruptive giant mollusca contagiosa in an adult psoriasis patient during efalizumab therapy. *Dermatology* 2008; 217(1): 85–86.
 53. Hayashi T, Hinoda Y, Takahashi T, et al. Idiopathic CD4+ T-lymphocytopenia with Bowen's disease. *Intern Med* 1997; 36(11): 822–824.
 54. Moin M, Farhoudi A, Movahedi M, et al. The clinical and laboratory survey of Iranian patients with hyper-IgE syndrome. *Scand J Infect Dis* 2006; 38(10): 898–903.
 55. Renner ED, Puck JM, Holland SM, et al. Autosomal recessive hyperimmunoglobulin E syndrome: a distinct disease entity. *J Pediatr* 2004; 144(1): 93–99.
 56. Mayumi M, Yamaoka K, Tsutsui T, et al. Selective immunoglobulin M deficiency associated with disseminated molluscum contagiosum. *Eur J Pediatr* 1986; 145(1-2): 99–103.
 57. Cotton DW, Cooper C, Barrett DF, et al. Severe atypical molluscum contagiosum infection in an immunocompromised host. *Br J Dermatol* 1987; 116(6): 871–876.
 58. Georgala S, Katoulis AC, Kanelleas A, et al. Letter: Human papilloma virus and molluscum contagiosum lesions related to infliximab therapy for psoriasis: a case series. *Dermatol Online J* 2012; 18(4): 9.
 59. Piaserico S, Sandini E, Peserico A, et al. Cutaneous viral infections in organ transplant patients. *G Ital Dermatol Venereol* 2014; 149: 409–415.
 60. Dann FJ and Tabibian P. Cutaneous diseases in human immunodeficiency virus-infected patients referred to the UCLA Immunosuppression Skin Clinic: reasons for referral and management of select diseases. *Cutis* 1995; 55(285-8): 85–88.
 61. Healy E, Meenan J, Mulcahy F, et al. The spectrum of HIV related skin diseases in an Irish population. *Ir Med J* 1993; 86(6): 188–190.
 62. Lanjewar DN, Bhosale A and Iyer A. Spectrum of dermatopathologic lesions associated with HIV/AIDS in India. *Indian J Pathol Microbiol* 2002; 45(3): 293–298.
 63. Matis WL, Triana A, Shapiro R, et al. Dermatologic findings associated with human immunodeficiency virus infection. *J Am Acad Dermatol* 1987; 17(5 Pt 1): 746–751.
 64. Hira SK, Wadhawan D, Kamanga J, et al. Cutaneous manifestations of human immunodeficiency virus in Lusaka, Zambia. *J Am Acad Dermatol* 1988; 19(3): 451–457.
 65. Goodman DS, Teplitz ED, Wishner A, et al. Prevalence of cutaneous disease in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex. *J Am Acad Dermatol* 1987; 17: 210–220.
 66. Ficarra G, Cortés S, Rubino I, et al. Facial and perioral molluscum contagiosum in patients with HIV infection. A report of eight cases. *Oral Surg Oral Med Oral Pathol* 1994; 78(5): 621–626.
 67. Kumarasamy N, Solomon S, Madhivanan P, et al. Dermatologic manifestations among human immunodeficiency virus patients in south India. *Int J Dermatol* 2000; 39(3): 192–195.
 68. Smith KJ, Skelton HG, Yeager J, et al. Cutaneous findings in HIV-1-positive patients: a 42-month prospective study. military medical consortium for the advancement of retroviral research (MMCARR). *J Am Acad Dermatol* 1994; 31: 746–754.
 69. Muñoz-Pérez MA, Rodríguez-Pichardo A, Camacho F, et al. Dermatological findings correlated with CD4 lymphocyte counts in a prospective 3 year study of 1161 patients with human immunodeficiency virus disease predominantly acquired through intravenous drug abuse. *Br J Dermatol* 1998; 139(1): 33–39.
 70. Singh A, Thappa DM and Hamide A. The spectrum of mucocutaneous manifestations during the evolutionary phases of HIV disease: an emerging Indian scenario. *J Dermatol* 1999; 26(5): 294–304.
 71. Kolokotronis A, Antoniadis D, Katsoulidis E, et al. Facial and perioral molluscum contagiosum as a manifestation of HIV infection. *Aust Dent J* 2000; 45(1): 49–52.
 72. Maurer T, Rodrigues LK, Ameli N, et al. The effect of highly active antiretroviral therapy on dermatologic disease in a longitudinal study of HIV type 1-infected women. *Clin Infect Dis* 2004; 38(4): 579–584.
 73. Mirowski GW, Hilton JF, Greenspan D, et al. Association of cutaneous and oral diseases in HIV-infected men. *Oral Dis* 1998; 4(1): 16–21.
 74. Koopman RJ, van Merriënboer FC, Vreden SG, et al. Molluscum contagiosum; a marker for advanced HIV infection. *Br J Dermatol* 1992; 126: 528–529.
 75. Ficarra G and Gaglioti D. Facial molluscum contagiosum in HIV-infected patients. *Int J Oral Maxillofac Surg* 1989; 18(4): 200–201.

76. Ikoona E, Kalyesubula I and Kawuma M. Ocular manifestations in paediatric HIV/AIDS patients in Mulago Hospital, Uganda. *Afr Health Sci* 2003; 3(2): 83–86.
77. Robinson MR, Udell IJ, Garber PF, et al. Molluscum contagiosum of the eyelids in patients with acquired immune deficiency syndrome. *Ophthalmology* 1992; 99(11): 1745–1747.
78. Cursiefen C, Grunke M, Dechant C, et al. Multiple bilateral eyelid molluscum contagiosum lesions associated with TNFalpha-antibody and methotrexate therapy. *Am J Ophthalmol* 2002; 134(2): 270–271.
79. Margo C and Katz NN. Management of periocular molluscum contagiosum in children. *J Pediatr Ophthalmol Strabismus* 1983; 20(1): 19–21.
80. Schornack MM, Siemsen DW, Bradley EA, et al. Ocular manifestations of molluscum contagiosum. *Clin Exp Optom* 2006; 89(6): 390–393.
81. Charteris DG, Bonshek RE and Tullo AB. Ophthalmic Molluscum contagiosum: clinical and immunopathological features. *Br J Ophthalmol* 1995; 79(5): 476–481.
82. Yoshinaga IG, Conrado LA, Schainberg SC, et al. Recalcitrant molluscum contagiosum in a patient with AIDS: combined treatment with CO(2) laser, trichloroacetic acid, and pulsed dye laser. *Lasers Surg Med* 2000; 27(4): 291–294.
83. Calista D, Boschini A and Landi G. Resolution of disseminated molluscum contagiosum with Highly Active Anti-Retroviral Therapy (HAART) in patients with AIDS. *Eur J Dermatol* 1999; 9(3): 211–213.
84. French MA, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. *HIV Med* 2000; 1(2): 107–115.
85. Ratnam I, Chiu C, Kandala NB, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. *Clin Infect Dis* 2006; 42(3): 418–427.
86. De Carvalho VO, Cruz CR, Noronha L, et al. An inflammatory reaction surrounding molluscum contagiosum as possible manifestation of immune reconstitution inflammatory syndrome in HIV infection. *Pediatr Dermatol* 2010; 27(6): 631–634.
87. Murdoch DM, Venter WD, Feldman C, et al. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. *AIDS* 2008; 22(5): 601–610.
88. Osei-Sekyere B and Karstaedt AS. Immune reconstitution inflammatory syndrome involving the skin. *Clin Exp Dermatol* 2010; 35(5): 477–481.
89. Pereira B, Fernandes C, Nachiambo E, et al. Exuberant molluscum contagiosum as a manifestation of the immune reconstitution inflammatory syndrome. *Dermatol Online J* 2007; 13(2): 6.
90. Micali G and Lacarrubba F. Augmented diagnostic capability using videodermatoscopy on selected infectious and non-infectious penile growths. *Int J Dermatol* 2011; 50(12): 1501–1505.
91. Ianhez M, Cestari Sda C, Enokihara MY, et al. Dermoscopic patterns of molluscum contagiosum: a study of 211 lesions confirmed by histopathology. *Bras Dermatol* 2011; 86(1): 74–79.
92. Zalaudek I, Giacomel J, Cabo H, et al. Entodermoscopy: a new tool for diagnosing skin infections and infestations. *Dermatology* 2008; 216(1): 14–23.
93. Ruocco E, Baroni A, Donnarumma G, et al. Diagnostic procedures in dermatology. *Clin Dermatol* 2011; 29(5): 548–556.
94. Trama JP, Adelson ME and Mordechai E. Identification and genotyping of molluscum contagiosum virus from genital swab samples by real-time PCR and Pyrosequencing. *J Clin Virol* 2007; 40(4): 325–329.
95. Piccinno R, Carrel CF, Menni S, et al. Preputial ectopic sebaceous glands mimicking molluscum contagiosum. *Acta Derm Venereol* 1990; 70(4): 344–345.
96. Feliciani C, Pennacchia I and Massi G. Adult self-healing papular mucinosis on genital skin. *Clin Exp Dermatol* 2009; 34(8): e760–e762.
97. Sims SM, McLean FW, Davis JD, et al. Vulvar lymphangioma circumscriptum: a report of 3 cases, 2 associated with vulvar carcinoma and 1 with hidradenitis suppurativa. *J Low Genit Tract Dis* 2010; 14(3): 234–237.
98. Vlastos AT, Malpica A and Follen M. Lymphangioma circumscriptum of the vulva: a review of the literature. *Obstet Gynecol* 2003; 101(5 Pt 1): 946–954.
99. Heath TC, Patel A, Fisher D, et al. Disseminated penicillium marneffeii: presenting illness of advanced HIV infection; a clinicopathological review, illustrated by a case report. *Pathology* 1995; 27(1): 101–105.
100. Singh PN, Ranjana K, Singh YI, et al. Indigenous disseminated *Penicillium marneffeii* infection in the state of Manipur, India: Report of four autochthonous cases. *J Clin Microbiol* 1999; 37: 2699–2702.
101. Supparatpinyo K, Khamwan C, Baosoung V, et al. Disseminated *Penicillium marneffeii* infection in Southeast Asia. *Lancet* 1994; 344: 110–113.
102. Chiewchanvit S, Chuaychoo B and Mahanupab P. Disseminated cryptococcosis presenting as molluscum-like lesions in three male patients with acquired immunodeficiency syndrome. *J Med Assoc Thai* 1994; 77(6): 322–326.
103. Murakawa GJ, Kerschmann R and Berger T. Cutaneous cryptococcus infection and AIDS. Report of 12 cases and review of the literature. *Arch Dermatol* 1996; 132: 545–548.
104. Dharmshale SN, Patil SA, Gohil A, et al. Disseminated cryptococcosis with extensive cutaneous involvement in AIDS. *Indian J Med Microbiol* 2006; 24(3): 228–230.
105. Durden FM and Elewski B. Cutaneous involvement with cryptococcus neoformans in AIDS. *J Am Acad Dermatol* 1994; 30(5 pt 2): 844–848.
106. Ghigliotti G, Carrega G, Farris A, et al. Cutaneous cryptococcosis resembling molluscum contagiosum in a homosexual man with AIDS. Report of a case and review of the literature. *Acta Derm Venereol* 1992; 72(3): 182–184.
107. Manfredi R, Mazzoni A, Nanetti A, et al. Morphologic features and clinical significance of skin involvement in patients with AIDS-related cryptococcosis. *Acta Derm Venereol* 1996; 76(1): 72–74.
108. Pema K, Diaz J, Guerra LG, et al. Disseminated cutaneous cryptococcosis. Comparison of clinical manifestations in the

- pre-AIDS and AIDS eras. *Arch Intern Med* 1994; 154(9): 1032–1034.
109. Ramdial PK, Calonje E, Sing Y, et al. Molluscum-like cutaneous cryptococcosis: a histopathological and pathogenetic appraisal. *J Cutan Pathol* 2008; 35(11): 1007–1013.
110. Rajpal S, Dwivedi S and Chaudhary SC. Disseminated cryptococcosis in an HIV-negative patient. *Trop Doct* 2009; 39(2): 114–115.
111. Imwidthaya P. Systemic fungal infections in Thailand. *J Med Vet Mycol* 1994; 32(5): 395–399.
112. Navarro EE, Tupasi TE, Verardo VM, et al. Disseminated histoplasmosis with unusual cutaneous lesions in a patient from the Philippines. *Am J Trop Med Hyg* 1992; 46(2): 141–145.
113. Hennessey NP, Parro EL and Cockerell CJ. Cutaneous pneumocystis carinii infection in patients with acquired immunodeficiency syndrome. *Arch Dermatol* 1991; 127(11): 1699–1701.
114. Hunt SJ, Nagi C, Gross KG, et al. Primary cutaneous Aspergillosis near central venous catheters in patients with the acquired immunodeficiency syndrome. *Arch Dermatol* 1992; 128(9): 1229–1232.
115. Castronovo C, Lebas E, Nikkels-Tassoudji N, et al. Viral infections of the pubis. *Int J STD AIDS* 2012; 23(1): 48–50.
116. Choong KY and Roberts LJ. Molluscum contagiosum, swimming and bathing: a clinical analysis. *Australas J Dermatol* 1999; 40: 89–92.
117. Shlay JC, McClung MW, Patnaik JL, et al. Comparison of sexually transmitted disease prevalence by reported level of condom use among patients attending an urban sexually transmitted disease clinic. *Sex Transm Dis* 2004; 31(3): 154–160.
118. Radcliffe KW, Daniels D and Evans BA. Molluscum contagiosum: a neglected sentinel infection. *Int J STD AIDS* 1991; 2(6): 416–418.
119. Van der Wouden JC, van der Sande R, Kruithof EJ, et al. Interventions for cutaneous molluscum contagiosum. *Cochrane Database Syst Rev* 2017; 5: CD004767. DOI: [10.1002/14651858.CD004767.pub4](https://doi.org/10.1002/14651858.CD004767.pub4).
120. Edwards S, Boffa MJ, Janier M, et al. 2020 *European guideline on the management of genital molluscum contagiosum*. *J Eur Acad Dermatol Venereol*. 2021; 35(1): 17–26. DOI: [10.1111/jdv.16856](https://doi.org/10.1111/jdv.16856)
121. Barton SE and Chard S. Facial molluscum: treatment with cryotherapy and podophyllotoxin. *Int J STD AIDS* 2002; 13(4): 277–278.
122. Al-Mutairi N, Al-Doukhi A, Al-Farag S, et al. Comparative study on the efficacy, safety, and acceptability of imiquimod 5% cream versus cryotherapy for molluscum contagiosum in children. *Pediatr Dermatol* 2010; 27(4): 388–394.
123. Qureshi A, Zeb M, Jalal-Ud-Din M, et al. Comparison of efficacy of 10% potassium hydroxide solution versus cryotherapy in treatment of molluscum contagiosum. *J Ayub Med Coll Abbottabad* 2016; 28: 382–385.
124. Handjani F, Behazin E and Sadati MS. Comparison of 10% potassium hydroxide solution versus cryotherapy in the treatment of molluscum contagiosum: an open randomized clinical trial. *J Dermatolog Treat* 2014; 25: 249–250.
125. Syed TA, Lundin S and Ahmad M. Topical 0.3% and 0.5% podophyllotoxin cream for self-treatment of molluscum contagiosum in males. A placebo-controlled, double-blind study. *Dermatology* 1994; 189(1): 65–68.
126. Teilla-Hamel D, Roux A and Loeb G. Pharmacokinetics and safety profile of topical podophyllotoxin (0.5% solution) on molluscum contagiosum in children. *Eur J Dermatol* 1996; 6: 437–440.
127. Hanna D, Hatami A, Powell J, et al. A prospective randomized trial comparing the efficacy and adverse effects of four recognized treatments of molluscum contagiosum in children. *Pediatr Dermatol* 2006; 23(6): 574–579.
128. Martín-García RF, García ME and Rosado A. Modified curettage technique for molluscum contagiosum. *Pediatr Dermatol* 2007; 24(2): 192–194.
129. Simonart T and De Maertelaer V. Curettage treatment for molluscum contagiosum: a follow-up survey study. *Br J Dermatol* 2008; 159(5): 1144–1147.
130. Harel A, Kutz AM, Hadj-Rabia S, et al. To treat molluscum contagiosum or not-curettage: an effective, well-accepted treatment modality. *Pediatr Dermatol* 2016; 33(6): 640–645.
131. Binder B, Weger W, Komericki P, et al. Treatment of molluscum contagiosum with a pulsed dye laser: pilot study with 19 children. *J Dtsch Dermatol Ges* 2008; 6: 121–125.
132. Michel JL. Treatment of molluscum contagiosum with 585 nm collagen remodeling pulsed dye laser. *Eur J Dermatol* 2004; 14(2): 103–106.
133. Chatproedprai S, Suwannakarn K, Wananukul S, et al. Efficacy of pulsed dyed laser (585 nm) in the treatment of molluscum contagiosum subtype 1. *Southeast Asian J Trop Med Public Health* 2007; 38(5): 849–854.
134. Dabis R, Rosbotham J, Jones L, et al. Potassium titanyl phosphate (KTP) laser treatment for molluscum contagiosum. *J Dermatolog Treat* 2006; 17(1): 45–47.
135. Nehal KS, Sarnoff DS, Gotkin RH, et al. Pulsed dye laser treatment of molluscum contagiosum in a patient with acquired immunodeficiency syndrome. *Dermatol Surg* 1998; 24(5): 533–535.
136. Hancox JG, Jackson J and McCagh S. Treatment of molluscum contagiosum with the pulsed dye laser over a 28-month period. *Cutis* 2003; 71(5): 414–416.
137. Hughes PS. Treatment of molluscum contagiosum with the 585-nm pulsed dye laser. *Dermatol Surg* 1998; 24(2): 229–230.
138. Hindson C and Cotterill J. Treatment of molluscum contagiosum with the pulsed tuneable dye laser. *Clin Exp Dermatol* 1997; 22(5): 255.
139. Liota E, Smith KJ, Buckley R, et al. Imiquimod therapy for molluscum contagiosum. *J Cutan Med Surg* 2000; 4: 76–82.
140. Hengge UR, Goos M and Arndt R. Topical treatment of warts and mollusca with Imiquimod. *Ann Intern Med* 2000; 132(1): 95.
141. Strauss RM, Doyle EL, Mohsen AH, et al. Successful treatment of molluscum contagiosum with topical imiquimod in a severely immunocompromised HIV-positive patient. *Int J STD AIDS* 2001; 12(4): 264–266.
142. Hengge UR, Esser S, Schultewolter T, et al. Self-administered topical 5% Imiquimod for the treatment of common warts and molluscum contagiosum. *Br J Dermatol* 2000; 143: 1026–1031.

143. Barba AR, Kapoor S and Berman B. An open label safety study of topical imiquimod 5% cream in the treatment of molluscum contagiosum in children. *Dermatol Online J* 2001; 7: 20–23.
144. Syed TA, Goswami J, Ahmadpour OA, et al. Treatment of molluscum contagiosum in males with an analog of Imiquimod 1% in cream: a placebo-controlled, double-blind study. *J Dermatol* 1998; 25: 309–313.
145. Lin HY, Linn G, Liu CB, et al. An immunocompromised woman with severe molluscum contagiosum that responded well to topical imiquimod: a case report and literature review. *J Low Genit Tract Dis* 2010; 14(2): 134–135.
146. Bayerl C, Feller G and Goerdts S. Experience in treating molluscum contagiosum in children with imiquimod 5% cream. *Br J Dermatol* 2003; 149 Suppl 66(suppl 66): 25–29.
147. Metkar A, Pande S and Khopkar U. An open, non-randomized, comparative study of imiquimod 5% cream versus 10% potassium hydroxide solution in the treatment of molluscum contagiosum. *Indian J Dermatol Venereol Leprol* 2008; 74: 614–618.
148. Puri N. A study on the use of imiquimod for the treatment of genital molluscum contagiosum and genital warts in female patients. *Indian J Sex Transm Dis AIDS* 2009; 30: 84–88.
149. Leslie KS, Dootson G and Sterling JC. Topical salicylic acid gel as a treatment for molluscum contagiosum in children. *J Dermatolog Treat* 2005; 16(5-6): 336–340.
150. Ohkuma M. Molluscum contagiosum treated with iodine solution and salicylic acid plaster. *Int J Dermatol* 1990; 29(6): 443–445.
151. Sadick N and Sorhaindo L. A comparative split-face study of cryosurgery and trichloroacetic acid 100% peels in the treatment of HIV-associated disseminated facial molluscum contagiosum. *Cutis* 2009; 83(6): 299–302.
152. Garrett SJ, Robinson R, Roenigk JK, Jr and Roenigk HH. Trichloroacetic acid peel of molluscum contagiosum in immunocompromised patients. *J Dermatol Surg Oncol* 1992; 18(10): 855–858.
153. Saryazdi S. The comparative efficacy of benzoyl peroxide 10% cream and tretinoin 0.05% cream in the treatment of molluscum contagiosum. Abstract 10th World Congress on Pediatric Dermatology. *Pediatr Dermatol* 2004; 21(3): 399.
154. Ormerod AD, White MI, Shah SA, et al. Molluscum contagiosum effectively treated with a topical acidified nitrite, nitric oxide liberating cream. *Br J Dermatol* 1999; 141(6): 1051–1053.
155. Romiti R, Ribeiro AP and Romiti N. Evaluation of the effectiveness of 5% potassium hydroxide for the treatment of molluscum contagiosum. *Pediatr Dermatol* 2000; 17(6): 495.
156. Romiti R, Ribeiro AP, Grinblat BM, et al. Treatment of molluscum contagiosum with potassium hydroxide: a clinical approach in 35 children. *Pediatr Dermatol* 1999; 16(3): 228–231.
157. Short KA, Fuller LC and Higgins EM. Double-blind, randomized, placebo-controlled trial of the use of topical 10% potassium hydroxide solution in the treatment of molluscum contagiosum. *Pediatr Dermatol* 2006; 23(3): 279–281.
158. Rajouria EA, Amatya A and Karn D. Comparative study of 5% potassium hydroxide solution versus 0.05% tretinoin cream for molluscum contagiosum in children. *Kathmandu Univ Med J (Kumj)* 2011; 9(36): 291–294.
159. Niizeki K and Hashimoto K. Treatment of molluscum contagiosum with silver nitrate paste. *Pediatr Dermatol* 1999; 16(5): 395–397.
160. Markum E and Baillie J. Combination of essential oil of *Melaleuca alternifolia* and iodine in the treatment of molluscum contagiosum in children. *J Drugs Dermatol* 2012; 11: 349–354.
161. Burke BE, Baillie JE and Olson RD. Essential oil of Australian lemon myrtle (*Backhousia citriodora*) in the treatment of molluscum contagiosum in children. *Biomed Pharmacother* 2004; 58: 245–247.
162. Vakharia PP, Chopra R, Silverberg NB, et al. Efficacy and safety of topical cantharidin treatment for molluscum contagiosum and warts: a systematic review. *Am J Clin Dermatol* 2018; 19: 791–803.
163. Jahnke MN, Hwang S, Griffith JL, et al. Cantharidin for treatment of facial molluscum contagiosum: A retrospective review. *J Am Acad Dermatol* 2018; 78: 198–200.
164. Guzman AK, Schairer DO, Garelik JL, et al. Safety and efficacy of topical cantharidin for the treatment of pediatric molluscum contagiosum: a prospective, randomized, double-blind, placebo-controlled pilot trial. *Int J Dermatol* 2018; 57: 1001–1006.
165. Coloe Dosal J, Stewart PW, Lin JA, et al. Cantharidin for the treatment of molluscum contagiosum: a prospective, double-blinded, placebo-controlled trial. *Pediatr Dermatol* 2014; 31: 440–449.
166. Moye VA, Cathcart S and Morrell DS. Safety of cantharidin: a retrospective review of cantharidin treatment in 405 children with molluscum contagiosum. *Pediatr Dermatol* 2014; 31: 450–454.
167. Cathcart S, Coloe J and Morrell DS. Parental satisfaction, efficacy, and adverse events in 54 patients treated with cantharidin for molluscum contagiosum infection. *Clin Pediatr (Phila)* 2009; 48: 161–165.
168. Coloe J and Morrell DS. Cantharidin use among pediatric dermatologists in the treatment of molluscum contagiosum. *Pediatr Dermatol* 2009; 26: 405–408.
169. Silverberg NB, Sidbury R and Mancini AJ. Childhood molluscum contagiosum: experience with cantharidin therapy in 300 patients. *J Am Acad Dermatol* 2000; 43: 503–507.
170. Antony F, Clich S, Ahmad A, et al. Double-blind placebo controlled study of oral cimetidine treatment for molluscum contagiosum. *Br J Dermatol* 2001; 145(59): 126.
171. Cunningham BB, Paller AS and Garzon M. Inefficacy of oral cimetidine for nonatopic children with molluscum contagiosum. *Pediatr Dermatol* 1998; 15: 71–72.
172. Dohil M and Prendiville JS. Treatment of molluscum contagiosum with oral cimetidine: clinical experience in 13 patients. *Pediatr Dermatol* 1996; 13: 310–312.
173. Calista D. Topical cidofovir for severe cutaneous human papillomavirus and molluscum contagiosum infections in patients with HIV/AIDS. A pilot study. *J Eur Acad Dermatol Venereol* 2000; 14(6): 484–488.
174. Toro JR, Wood LV, Patel NK, et al. Topical cidofovir: a novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1. *Arch Dermatol* 2000; 136: 983–985.

175. Davis EG, Thrasher A, Lacey K, et al. Topical Cidofovir for severe molluscum contagiosum. *Lancet* 1999; 353(9169): 2042.
176. Zabawski EJ and Cockerell CJ. Topical cidofovir for molluscum contagiosum in children. *Pediatr Dermatol* 1999; 16: 414–415.
177. Meadows KP, Tyring SK, Pavia AT, et al. Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir. *Arch Dermatol* 1997; 133: 987–990.
178. Ibarra V, Blanco JR, Oteo JA, et al. Efficacy of cidofovir in the treatment of recalcitrant molluscum contagiosum in an AIDS patient. *Acta Derm Venereol* 2000; 80: 315–316.
179. Erickson C, Driscoll M and Gaspari A. Efficacy of intravenous cidofovir in the treatment of giant molluscum contagiosum in a patient with human immunodeficiency virus. *Arch Dermatol* 2011; 147(6): 652–654.
180. Nelson MR, Chard S and Barton SE. Intralesional interferon for the treatment of recalcitrant molluscum contagiosum in HIV antibody positive individuals—a preliminary report. *Int J STD AIDS* 1995; 6(5): 351–352.
181. Hourihane J, Hodges E, Smith J, et al. Interferon alpha treatment of molluscum contagiosum in immunodeficiency. *Arch Dis Child* 1999; 80(1): 77–79.
182. Kilic SS and Kilicbay F. Interferon-alpha treatment of molluscum contagiosum in a patient with hyperimmunoglobulin E syndrome. *Pediatrics* 2006; 117(6): e1253–1255.
183. Sen S and Bhaumik P. Resolution of giant Molluscum contagiosum with antiretroviral therapy. *Indian J Dermatol Venereol Leprol* 2008; 74(3): 267–268.
184. Sen S, Goswami BK, Karji N, et al. Disfiguring Molluscum contagiosum in a HIV-positive patient responding to antiretroviral therapy. *Indian J Dermatol* 2009; 54(2): 180–182.
185. Humi MA, Böhlen L, Furrer H, et al. Complete regression of giant molluscum contagiosum lesions in an HIV-infected patient following combined antiretroviral therapy with saquinavir, zidovudine and lamivudine. *AIDS* 1997; 11(14): 1784–1785.
186. Cattelan AM, Sasset L, Corti L, et al. A complete remission of recalcitrant molluscum contagiosum in an AIDS patient following highly active antiretroviral therapy (HAART). *J Infect* 1999; 38(1): 58–60.
187. Hicks CB, Myers SA and Giner J. Resolution of intractable molluscum contagiosum in a human immunodeficiency virus-infected patient after institution of antiretroviral therapy with ritonavir. *Clin Infect Dis* 1997; 24(5): 1023–1025.
188. Martin P. Interventions for molluscum contagiosum in people infected with human immunodeficiency virus: a systematic review. *Int J Dermatol* 2016; 55: 956–966.